Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair® in chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 30, Issue , 2015, Pages 128-133

  Hoshino, Makoto ^a   Ohtawa, Junichi ^a   Akitsu, Kenta ^a  

^a International University of Health and Welfare   (Japan)

Author keywords

Ai; Airway geometry; Ao; BSA; FVC; IC; ICS; LABA; LAMA; Long acting muscarinic receptor antagonist; Long acting 2 adrenergic receptor agonist; Pulmonary function; Pulmonary hyperinflation; Quantitative computed tomography; SGRQ; T; WA; WA Ao

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; INDACATEROL; TIOTROPIUM BROMIDE; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG COMBINATION; FLUTICASONE, SALMETEROL DRUG COMBINATION; GLUCOCORTICOID; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

AGED; AIRWAY; ARTICLE; BODY SURFACE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DRUG EFFECT; DRUG INDUCED HEADACHE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GEOMETRY; HUMAN; INSPIRATORY CAPACITY; LUMINAL AREA; LUNG FUNCTION; MALE; MUSCLE SPASM; PERCENTAGE WALL AREA; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; RHINOPHARYNGITIS; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; THICKNESS; TOTAL AREA OF THE AIRWAY; WALL AREA; WALL THICKNESS; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE;

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; QUINOLONES; SCOPOLAMINE DERIVATIVES; SPIROMETRY;

EID: 84922734756     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.08.002     Document Type: Article

References (41)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2010, http://www.goldcopd.org/.
2. Vogelmeier C., Kardos P., Harari S., Stenglein S., Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008, 102:1511-1520.
3. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555.
4. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
5. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Zaagsma J., Mueller A., et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010, 104:995-1004.
6. Tashkin D.P., Pearle J., Iezzoni D., Varghese S.T. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009, 6:17-25.
7. Mahler D.A., D'Urzo A., Bateman E.D., Ozkan S.A., White T., Peckitt C., et al. INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67:781-788.
8. Mahler D.A., Wire P., Horstman D., Chang C.N., Yates J., Fischer T., et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 166:1084-1091.
9. Hanania N.A.1, Darken P., Horstman D., Reisner C., Lee B., Davis S., et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003, 124:834-843.
10. Calverley P., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., et al. TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456.
11. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. NEngl J Med 2007, 356:775-789.
12. Celli B.R., Thomas N.E., Anderson J.A., Ferguson G.T., Jenkins C.R., Jones P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338.
13. Nakano Y., Muro S., Sakai H., Hirai T., Chin K., Tsukino M., et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000, 162:1102-1108.
14. Hasegawa M., Nasuhara Y., Onodera Y., Makita H., Nagai K., Fuke S., et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:1309-1315.
15. Bergin C., Müller N., Nichols D.M., Lillington G., Hogg J.C., Mullen B., et al. The diagnosis of emphysema. A computed tomographic-pathologic correlation. Am Rev Respir Dis 1986, 133:541-546.
16. Thurlbeck W.M., Müller N.L. Emphysema: definition, imaging, and quantification. Am J Roentgenol 1994, 163:1017-1025.
17. Orlandi I., Moroni C., Camiciottoli G., Bartolucci M., Pistolesi M., Villari N., et al. Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology 2005, 234:604-610.
18. Hoshino M., Ohtawa J. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in COPD. Respiration 2013, 86:280-287.
19. Okazawa M., Müller N., McNamara A.E., Child S., Verburgt L., Paré P.D. Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med 1996, 154:1557-1562.
20. Matsuoka S., Kurihara Y., Yagihashi K., Hoshino M., Nakajima Y. Airway dimensions on inspiratory and expiratory multisection CT in chronic obstructive pulmonary disease: correlation with airflow limitation. Radiology 2008, 248:1042-1049.
21. The Committee of Pulmonary Physiology, Japanese Respiratory Society Guidelines for pulmonary function tests. Spirometry, flow volume curve, diffusion capacity of the lung 2004, The Japanese Respiratory Society, Tokyo, [in Japanese].
22. Jones P.W., Quirk F.H., Baveystock C.M., Littlejohns P. Aself-complete measure for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
23. Hasegawa M., Makita H., Nasuhara Y., Odajima N., Nagai K., Ito Y., et al. Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax 2009, 64:32-38.
24. Tanabe N., Muro S., Oguma T., Sato S., Kiyokawa H., Takahashi T., et al. Computed tomography assessment of pharmacological lung volume reduction induced by bronchodilators in COPD. COPD 2012, 9:401-408.
25. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. NEngl J Med 2004, 350:2645-2653.
26. Gosens R., Zaagsma J., Meurs H., Halayko A.J. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006, 9(7):73.
27. Racké K., Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm Pharmacol Ther 2004, 17:181-198.
28. Barnes P.J. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004, 1:345-351.
29. Hoshino M., Ohtawa J. Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients. Respirology 2014, 19:403-410.
30. Kistemaker L.E., Oenema T.A., Meurs H., Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci 2012, 91:1126-1133.
31. Newton M.F., O'Donnell D.E., Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002, 121:1042-1050.
32. O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160:542-549.
33. O'Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24:86-94.
34. Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003, 124:1743-1748.
35. O'Donnell D.E., Flüge T., Gerken F., Hamilton A., Webb K., Aguilaniu B., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840.
36. Beier J., Beeh K.M., Brookman L., Peachey G., Hmissi A., Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009, 22:492-496.
37. Calverley P., Pauwels R.A., Jones P.W., Anderson J.A., Vestbos J. The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis 2006, 1:209-218.
38. Jenkins C.R., Jones P.W., Calverley P.M., Celli B., Anderson J.A., Ferguson G.T., et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 30:59.
39. Rabe K.F., Timmer W., Sagkriotis A., Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008, 134:255-262.
40. Vogelmeier C.F., Bateman E.D., Pallante J., Alagappan V.K., D'Andrea P., Chen H., et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013, 1:51-60.
41. Aysola R.S., Hoffman E.A., Gierada D., Wenzel S., Cook-Granroth J., Tarsi J., et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008, 134:1183-1191.